| Description | Cenupatide acetate is an urokinase plasminogen activator receptor (uPAR) inhibitor for treating disorders associated altered cell migration, such as cancer. |
| In vivo | Cenupatide通过抑制uPAR与甲酰肽受体(FPRs)的结合，在链脲佐菌素(STZ)诱导的大鼠糖尿病模型中改善肾损伤[1]。 |
| Synonyms | Cenupatide acetate(1006388-38-0 Free base) |
| molecular weight | 677.8 |
| Molecular formula | C30H51N11O7 |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | H2O: 10 mg/mL (14.8 mM), Sonication is recommended. DMSO: 5 mg/mL (7.4 mM), Sonication is recommended. |
| References | 1. Massimo Dal Monte, et al. Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy. J Cell Mol Med. 2019 Feb;23(2):1034-1049. |